| Eligo Bioscience–SEVERAL: investment, 202312 financing round Series B $30m led by Sanofi Ventures |
2023-12-05 |
| Exscientia–Open Philanthropy: grant, 202312– grant $2.3m for research in host interferon response as therapeutic approach for pandemic influenza |
2023-12-05 |
| IBA (BE)–Univ Kansas: proton therapy, 202312– colllab research using ConformalFLASH technology on ProteusONE system with KUMC |
2023-12-05 |
| Carmot Therapeutics–Roche: investment, 202312– acquisition $2.7b upfront + $400m milestones by Roche |
2023-12-04 |
| Freeline Therapeutics–Syncona: credit, 202311–202411 secured convertible loan note up to $15m with 12% interest + conversion price of $6.5/ADS |
2023-11-22 |
| Freeline Therapeutics–Syncona: investment, 202311– acquisition all remaining shares $6.5/ADS in going-private valuing entire issued capital at $28.3m |
2023-11-22 |
| Vivodyne–Bison Ventures: investment, 202311 seed financing round totalling $38m incl co-investor Bison Ventures |
2023-11-22 |
| Vivodyne–CS Ventures: investment, 202311 seed financing round totalling $38m incl co-investor CS Ventures |
2023-11-22 |
| Vivodyne–Kairos Ventures: investment, 202311 seed financing round totalling $38m incl co-investor Kairos Ventures |
2023-11-22 |
| Vivodyne–Khosla Ventures: investment, 202311 seed financing round totalling $38m incl lead investor Khosla Ventures |
2023-11-22 |
| Vivodyne–KKH Advisors: public relations, 202311 service existent by KKH Advisors |
2023-11-22 |
| Vivodyne–MBX Capital: investment, 202311 seed financing round totalling $38m incl co-investor MBX Capital |
2023-11-22 |
| Vivodyne–SEVERAL: investment, 202311 seed financing round $38m led by Khosla Ventures |
2023-11-22 |
| Caraway Therapeutics–Merck (US): investment, 202311– acquisition up to $610m by Merck SIGNED |
2023-11-21 |
| Evolva–Lallemand: investment, 202311– acquisitions of operations via 100% of Evolva AG for CHF20m + CHF10m milestones by Danstar Ferment AG |
2023-11-21 |
| Quotient Therapeutics–Flagship Pioneering: investment, 202311 Quotient Tx unveiled with initial $50m commitment from Flagship Pioneering |
2023-11-21 |
| Roche–Nvidia: AI-based drug r+d, 202311– collab strategic alliance multi-year of Genentech with Nvidia using Nvidia DGX Cloud + Nvidia BioNemo |
2023-11-21 |
| T-Therapeutics–SEVERAL: investment, 202311 financing round Series A Ł48m |
2023-11-15 |
| Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures |
2023-11-14 |
| VectorY–Insight Partners: investment, 202311 financing round Series A totalling €129m incl co-investor Insight Partners |
2023-11-13 |
| VectorY–Merck (US): investment, 202311 financing round Series A totalling €129m incl co-investor MRL Ventures Fund |
2023-11-13 |
| VectorY–SEVERAL: investment, 202311 financing round Series A €129m co-led by EQT Life Sciences + Forbion Growth Opportunities Fund |
2023-11-13 |
| ViaNautis Bio–4BIO Ventures: investment, 202311 financing round Series A totalling $25m incl co-lead investor 4BIO Capital |
2023-11-13 |
| ViaNautis Bio–BGF: investment, 202311 financing round Series A totalling $25m incl co-lead investor BGF |
2023-11-13 |
| ViaNautis Bio–Cystic Fibrosis Foundation: investment, 202311 financing round Series A totalling $25m incl co-investor Cystic Fibrosis Foundation |
2023-11-13 |
| ViaNautis Bio–Origin Capital: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Origin Capital |
2023-11-13 |
| ViaNautis Bio–SEVERAL: investment, 202311 financing round Series A $25m led by 4BIO Capital + BGF + UCB Ventures |
2023-11-13 |
| ViaNautis Bio–UCB: investment, 202311 financing round Series A totalling $25m incl co-lead investor UCB Ventures |
2023-11-13 |
| Cromatic–SEVERAL: investment, 2023011 seed financing round $5.3m co-led by LifeX Ventures + AgFunder |
2023-11-09 |
| Kynexis–Forbion: investment, 202311 financing round Series A totalling €57m incl co-founding + lead investor Forbion |
2023-11-07 |
| Kynexis–SEVERAL: investment, 202311 financing round Series A €57m led by Forbion |
2023-11-07 |
| Kynexis–Sunstone Life Science: investment, 202311 financing round Series A totalling €57m incl co-investor Sunstone Life Science Ventures |
2023-11-07 |
| Kynexis–Ysios Capital: investment, 202311 financing round Series A totalling €57m incl co-founding + co-investor Ysios Capital |
2023-11-07 |
| Valanx Biotech–SEVERAL: investment, 202311 growth financing round €2.3m incl equity + public funding led by SkyGene |
2023-11-07 |
| Valanx Biotech–SOSV: investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor SOSV |
2023-11-07 |
| Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV |
2023-11-02 |
| Cambrium–Essential Capital: investment, 202311 seed financing round totalling €8m incl lead investor Essential Capital |
2023-11-01 |
| Cambrium–Hof Capital: investment, 202311 seed financing round totalling €8m incl co-investor Hof Capital |
2023-11-01 |
| Cambrium–SEVERAL: investment, 202311 seed financing round €8m led by Essential Capital |
2023-11-01 |
| Cambrium–SNR: investment, 202311 seed financing round totalling €8m incl co-investor SNR |
2023-11-01 |
| Cambrium–Valor Equity Partners: investment, 202311 seed financing round totalling €8m incl co-investor Valor Equity Partners |
2023-11-01 |
| Kynexis–Mitsubish Chemical: KAT-II inhibitor, 202311c– license excl ww rights to develop + commercialize KYN-5356 from MTPC |
2023-11-01 |
| LimFlow–Inari Medical: investment, 202311– acquisition $250m cash upfront at closing + $165m by Inari Medical |
2023-11-01 |
| Carlyle–SEVERAL: investment, 202310 final closing $356m of Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) |
2023-10-30 |
| MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets |
2023-10-30 |
| Moderna–Caris Life Sciences: genomic profiling, 202310– strategic collab multi-year clinico-genomics data for mRNA-based precision cancer drugs |
2023-10-24 |
| Merck (US)–Daiichi Sankyo: antibody-drug conjugates, 202310– collab developm + commerc 3 DXd ADCs ww excl JP $4b upfront + $18b milestones |
2023-10-19 |
| Olink–Thermo Fisher: investment, 202310– acquisition cash tender offer $3.1b at $26/share by Thermo Fisher |
2023-10-17 |
| Servier–Owkin: AI-based drug discovery, 202310– collab using AI for RnD of precision therapeutics for cancer + other indications |
2023-10-17 |
| VedaBio–SEVERAL: investment, 202310 initial funding >$40m led by OMX Ventures at announced launch |
2023-10-17 |
| AOA Dx–SEVERAL: investment, 202310 financing round $17m led by Good Grwoth Capital bringing total raised to $24m |
2023-10-12 |
| BioNTech–MediLink Therapeutics: antibody-drug conjugates, 202310– collab + ww license excl China $70m upfront + $>1b milestones for anti-HER3 ADC |
2023-10-12 |
| Agomab Therapeutics–Canaan Partners: investment, 202310 financing round Series C totalling $100m incl new + co-investor Canaan |
2023-10-10 |
| Agomab Therapeutics–EQT: investment, 202310 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences |
2023-10-10 |
| Agomab Therapeutics–Fidelity: investment, 202310 financing round Series C totalling $100m incl lead investor Fidelity Mgt and Research |
2023-10-10 |
| Agomab Therapeutics–KKR: investment, 202310 financing round Series C totalling $100m incl new + co-investor Dawn Biopharma |
2023-10-10 |
| Agomab Therapeutics–OTHER: investment, 202310 financing round Series C totalling $100m incl existing investors |
2023-10-10 |
| Agomab Therapeutics–SEVERAL: investment, 202310 financing round Series C $100m (€94.9m) led by Fidelity Mgt and Research Company |
2023-10-10 |
| Mana.bio–SEVERAL: investment, 202310 seed financing round $19.5m co-led by Andreessen Horowitz B+H+ Base4 Capital + NFX + LionBird + Technion |
2023-10-10 |
| AstronauTx–SEVERAL: investment, 202310 financing round Series A ťŁ48m led by Novartis Venture Fund |
2023-10-09 |
| LimmaTech Biologics–SEVERAL: investment, 202310 financing round Series A $37m co-led by Adjuvant Capital + AXA IM Alts + Novo REPAIR Impact Fund |
2023-10-09 |
| Mirati–BMS: investment, 202310– acquisition $4.8b in cash (incl $1.1b cash of Mirati) at $58/share plus $1b CVR at $12/CVR |
2023-10-08 |
| Precede Biosciences–5AM Ventures: investment, <202310 seed financing round incl existing co-founding investor 5AM Ventures |
2023-10-05 |
| Precede Biosciences–5AM Ventures: investment, <=202310 financing round Series A incl existing + co-lead investor 5AM Ventures |
2023-10-05 |
| Precede Biosciences–BMS: investment, <=202310 financing round Series A incl new + co-investor BMS |
2023-10-05 |
| Precede Biosciences–Harvard Univ: investment, <202310 seed financing round incl investor Binney Street Capital |
2023-10-05 |
| Precede Biosciences–Illumina: investment, <=202310 financing round Series A incl new + co-investor Illumina Ventures |
2023-10-05 |
| Precede Biosciences–Lilly Asia Ventures: investment, <=202310 financing round Series A incl new + co-lead investor Lilly Asia Ventures |
2023-10-05 |
| Precede Biosciences–Osage Partners: investment, <=202310 financing round Series A incl new + co-investor Osave University Partners |
2023-10-05 |
| Precede Biosciences–Qatar (govt): investment, <=202310 financing round Series A incl new + co-investor Qatar Investment Authority |
2023-10-05 |
| Precede Biosciences–SEVERAL: investment, <202310 seed financing round with co-founder 5AM Ventures + Binney Street Capital |
2023-10-05 |
| Precede Biosciences–SEVERAL: investment, <=202310 financing round Series A announced when Precede emerged from stealth with $57m in backing |
2023-10-05 |
| MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker |
2023-10-04 |
| Point Biopharma–Lilly: investment, 202310– cash tender offer $1.4b by Lilly at $12.5/share |
2023-10-03 |
| Mogrify–SEVERAL: investment, 202310 financing round Series A extension $10m bringing total Series A to $46m led by Astellas VM & Parkwalk Advisors |
2023-10-02 |
| MetrioPharm–SEVERAL: investment, 202310c financing round Series D 1st closing CHF18m |
2023-10-01 |
| Abivax–SEVERAL: investment, 202309–202310 European private placement €17.9m with 1.6m new ordinary shares at €10.99/share |
2023-09-29 |
| Abivax–SEVERAL: investment, 202309–202310 US IPO $217m with 18.7m ADSs (new ordinary shares) at $11.6/ADS at Nasdaq Global Market |
2023-09-29 |
| Laverock Therapeutics–Lilly: investment, 202309 seed financing round totalling Ł13.5m incl co-investor Eli Lilly |
2023-09-28 |
| Laverock Therapeutics–Mattioli Woods: investment, 202309 seed financing round totalling Ł13.5m incl co-investor Maven Capital Partners |
2023-09-28 |
| Laverock Therapeutics–Mercia: investment, 202309 seed financing round totalling Ł13.5m incl co-investor Mercia Ventures |
2023-09-28 |
| Laverock Therapeutics–SEVERAL: investment, 202309 seed financing round expansion to Ł13.5m led by Calculus Capital |
2023-09-28 |
| BioProtect–MVM: investment, 202309 financing round totalling $28m incl new + lead investor MVM Partners |
2023-09-27 |
| BioProtect–SEVERAL: investment, 202309 financing round $28m led by MVM Partners |
2023-09-27 |
| Co.faktor–Cytel: investment, 202309 acquisition of Co.faktor GmbH by Cytel Inc |
2023-09-26 |
| Cytel–BioStrata: public relations, 202309 service existent by BioStrata |
2023-09-26 |
| Novo Group–Valo Health: AI-based drug discovery, 202309– collab + license up to $2.7b using Opal Computation Platform in cardiometabolic disease |
2023-09-25 |
| Pepceuticals–Biosynth: investment, 202309 acquisition of Pepceuticals Ltd by Biosynth |
2023-09-25 |
| Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202309–203309 supply 10y >$100m of nca lutetium-177 to Point Biopharma |
2023-09-25 |
| BenevolentAI–FTI Consulting: public relations, 202309 service existent by FTI Consulting |
2023-09-20 |
| Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront |
2023-09-20 |
| Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties |
2023-09-20 |
| Broken String Biosciences–Illumina: investment, 202309 financing round Series A totalling $15m incl new + co-lead investor Illumina Ventures |
2023-09-18 |
| Broken String Biosciences–SEVERAL: investment, 202309 financing round Series A $15m co-led by Illumina Ventures + Mérieux Equity Partners |
2023-09-18 |
| Broken String Biosciences–Tencent: investment, 202309 financing round Series A totalling $15m incl existing + co-investor Tencent |
2023-09-18 |
| Scinai Immunotherapeutics–SEVERAL: investment, 202309 registered direct offering $1.33m with 1.15m ADSs at $1.16/ADS |
2023-09-15 |
| RayzeBio–PeptiDream: investment, 202309 DIVESTMENT via IPO ./.$20.9m with 1.163m shares sold by PeptiDream at $18/share resulting 2% shareholding |
2023-09-14 |
| RayzeBio–SEVERAL: investment, 202309 IPO $336.7m with 16.1m+2.6m new shares at $18/share (excl 1.163m shares sold by PeptiDream) |
2023-09-14 |
| BioLamina–Lauxera: investment, 202309 investment €17m by Lauxera Growth I fund |
2023-09-12 |
| Consilium–ICR: investment, 202309 acquisition of Consilium Strategic Communications by ICR |
2023-09-12 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
